Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation.
Models for testing new drugs for the treatment of hormone-dependent prostate cancer are restricted to a few in vivo rat tumour lines; most of them originating from the Dunning R3327 adenocarcinoma. The original tumour and the R3327-H line grow rather slowly leading to a long duration of therapeutic experiments. The R3327-G subline can be transplanted as a cell suspension or tumour fragments, which give rise to fast and rather homogeneously growing androgen-dependent tumours. Their growth is strongly inhibited by castration or administration of diethylstilbestrol. Experiments were terminated 5 weeks after transplantation. Best results were obtained when treatment was started 1 day after transplantation. Histological sections showed therapy-dependent changes in the microarchitecture of these prostate tumours. The direct inhibitory effect of antiandrogens on prostate tumours was demonstrated when castrated, testosterone-propionate-supplemented animals were used. The short duration of experiments and reproducible responses to standard therapies are the advantages of this tumour model.
Kager
M
M
Institut für Pharmazie, Universität Regensburg, Federal Republic of Germany.
Spruss
T
T
Schneider
M R
MR
von Angerer
E
E
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000818:Animals; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D008297:Male; D009368:Neoplasm Transplantation; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344
D000726:Androgen Antagonists